Literature DB >> 11574207

Wedge resection of the bronchus: an alternative bronchoplastic technique for preservation of lung tissue.

C Kotoulas1, G Lazopoulos, C Foroulis, M Konstantinou, P Tomos, A Lioulias.   

Abstract

OBJECTIVES: We present a modified wedge resection of the bronchus, as an alternative bronchoplastic technique for lung resection, in cases of patients with or without adequate pulmonary reserve to undergo a pneumonectomy, in order to preserve lung tissue.
METHODS: Seventeen patients underwent a major lung resection with wedge resection of the bronchus for non-small cell lung cancer (NSCLC) in our department, from March 1995 to October 1999. A right-sided NSCLC were diagnosed in 17 males, with a mean age 62.5+/-6.6 (range 51-72) years. Further workup was free of metastatic disease. All patients underwent a right posterolateral thoracotomy, under general anesthesia with a double lumen endotracheal tube. Twelve right upper lobectomies, four right upper and middle lobectomies and one carinal resection were performed. The wedge resection of the bronchus carried out longitudinally, along the bronchial tree, and the bronchial defect was reapproximated transversely, in a single-layer, with interrupted non-absorbable suture. The frozen section of the distal margin of the resected bronchus was negative for malignancy in all patients. Extended mediastinal lymph node dissection followed each lung resection.
RESULTS: The pathology report showed 12 squamous-cell carcinomas, three adenocarcinomas, one adenosquamous carcinoma and one neuroendocrine carcinoma. The differentiation of the carcinomas was well in two cases, moderate in ten and poor in five. The pTNM stage was IB in four patients (23.5%), IIA in one (5.9%), IIB in eight (47.1%) and IIIA in four (23.5%). The median disease-free distal margin of the bronchus was 5 mm (range 2-15 mm). The average postoperative hospital stay was 15 days (range 12-28 days). The morbidity and mortality rate was 11.8 and 5.9%, respectively. Postoperative follow-up was every 6 months. The average survival is 20.0+/-15.2 months (range 1-54 months). There are 12 patients alive, and their follow-up is negative for locoregional recurrence or distant metastasis. The survival study showed no significantly statistic relation to the histologic type, cancer differentiation, pTNM stage, and disease-free distal margin of resection larger or less than 0.5 cm (Kaplan-Meier study log rank method).
CONCLUSIONS: The wedge resection of the bronchus as a bronchoplastic procedure is an easy, fast and safe technique of reparation of the bronchial tree. It presents not only a low rate of morbidity and mortality, but also a satisfactory survival.

Entities:  

Mesh:

Year:  2001        PMID: 11574207     DOI: 10.1016/s1010-7940(01)00889-2

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Uniportal video-assisted thoracoscopic bronchoplastic and carinal sleeve procedures.

Authors:  Diego Gonzalez-Rivas; Yang Yang; Dmitrii Sekhniaidze; Tomaz Stupnik; Ricardo Fernandez; Jiang Lei; Yuming Zhu; Gening Jiang
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

Review 2.  History and current status of bronchoplastic surgery for lung cancer.

Authors:  Jean Deslauriers; François Tronc; Jocelyn Grégoire
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-01-22

3.  Deeper wedge resection and parenchymal-sparing bronchoplasty of the secondary carina: an alternative surgical technique for removal of tumor located at the orifice of upper lobar bronchus.

Authors:  An Wang; Xiaofeng Chen; Dayu Huang; Shaohua Wang
Journal:  J Cardiothorac Surg       Date:  2017-06-13       Impact factor: 1.637

4.  Nodular-type central squamous cell lung carcinoma cured by intraluminal bronchoscopic treatment: A case report.

Authors:  Hikaru Aoki; Keigo Uchimura; Tatsuya Imabayashi; Yuji Matsumoto; Masahiro Higashiyama; Shun-Ichi Watanabe; Takaaki Tsuchida
Journal:  Thorac Cancer       Date:  2021-07-28       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.